3 Global Penny Stocks With Market Caps Under US$900M To Watch

Global markets have been navigating a challenging landscape marked by geopolitical tensions, fluctuating oil prices, and persistent inflation concerns. Amidst this backdrop, the concept of penny stocks remains relevant as these smaller or newer companies can offer unique growth opportunities at lower price points. When backed by strong financial health and solid fundamentals, penny stocks can present underappreciated chances for significant returns.

Top 10 Penny Stocks Globally

Name	Share Price	Market Cap	Rewards & Risks
Foresight Group Holdings (LSE:FSG)	£3.545	£401.58M	✅ 5 ⚠️ 0 View Analysis >
TK Group (Holdings) (SEHK:2283)	HK$2.29	HK$1.93B	✅ 4 ⚠️ 1 View Analysis >
Angler Gaming (NGM:ANGL)	SEK3.60	SEK269.95M	✅ 4 ⚠️ 2 View Analysis >
Angler Gaming (DB:0QM)	€0.31	€228.7M	✅ 4 ⚠️ 3 View Analysis >
PC Partner Group (SGX:PCT)	SGD1.35	SGD523.64M	✅ 4 ⚠️ 2 View Analysis >
CNMC Goldmine Holdings (Catalist:5TP)	SGD1.51	SGD611.99M	✅ 4 ⚠️ 2 View Analysis >
Focus Point Holdings Berhad (KLSE:FOCUSP)	MYR0.485	MYR298.25M	✅ 5 ⚠️ 2 View Analysis >
Integrated Diagnostics Holdings (LSE:IDHC)	$0.565	$328.45M	✅ 4 ⚠️ 1 View Analysis >
Bosideng International Holdings (SEHK:3998)	HK$3.96	HK$47.66B	✅ 4 ⚠️ 2 View Analysis >
Scott Technology (NZSE:SCT)	NZ$2.35	NZ$195.1M	✅ 4 ⚠️ 1 View Analysis >

Click here to see the full list of 3,596 stocks from our Global Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Antengene (SEHK:6996)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Antengene Corporation Limited is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies in Greater China and internationally, with a market cap of HK$3.16 billion.

Operations: Antengene has not reported any revenue segments.

Market Cap: HK$3.16B

Antengene Corporation Limited, with a market cap of HK$3.16 billion, remains a clinical-stage biopharmaceutical company focused on oncology therapies and has reported sales of CNY 105.34 million for 2025. Despite being unprofitable, it has reduced its losses over the past five years by an average of 48.7% annually and maintains sufficient cash runway for more than two years if current trends continue. Recent developments include an agreement with UCB granting exclusive rights to develop ATG-201, potentially yielding upfront payments of US$80 million and future milestones exceeding US$1 billion, alongside ongoing innovative research in T-cell engagers and ADCs targeting various cancers.

• Click to explore a detailed breakdown of our findings in Antengene's financial health report.
• Review our growth performance report to gain insights into Antengene's future.

Jiangsu Jiangnan High Polymer FiberLtd (SHSE:600527)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Jiangsu Jiangnan High Polymer Fiber Co., Ltd specializes in the production and sale of polyester tops and composite staple fibers both in China and internationally, with a market cap of CN¥4.34 billion.

Operations: No specific revenue segments are reported for this company.

Market Cap: CN¥4.34B

Jiangsu Jiangnan High Polymer Fiber Co., Ltd, with a market cap of CN¥4.34 billion, trades significantly below its estimated fair value and maintains more cash than total debt, suggesting financial stability. The company's short-term assets comfortably cover both short- and long-term liabilities, but recent earnings have been impacted by large one-off items. Despite this, the firm has experienced negative earnings growth over the past five years. Its dividend yield of 1.94% is not well-covered by earnings, and the board's average tenure indicates limited experience at 2.1 years, potentially affecting strategic direction.

• Unlock comprehensive insights into our analysis of Jiangsu Jiangnan High Polymer FiberLtd stock in this financial health report.
• Explore historical data to track Jiangsu Jiangnan High Polymer FiberLtd's performance over time in our past results report.

Dongguan Kingsun OptoelectronicLtd (SZSE:002638)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Dongguan Kingsun Optoelectronic Co., Ltd. manufactures and sells LED lighting products both in China and internationally, with a market cap of CN¥5.98 billion.

Operations: The company's revenue is primarily derived from its Semiconductor Lighting segment, which generated CN¥399.21 million.

Market Cap: CN¥5.98B

Dongguan Kingsun Optoelectronic Co., Ltd. has a market cap of CN¥5.98 billion, with its semiconductor lighting segment generating CN¥399.21 million in revenue. Despite being unprofitable, the company has reduced losses by 6% annually over five years and benefits from an experienced management team with an average tenure of 3.8 years. It is debt-free and possesses sufficient cash runway for over three years based on current free cash flow levels, indicating financial resilience. However, its return on equity remains negative at -18.74%, and the board's relatively new tenure of 2.8 years may impact strategic decisions.

• Take a closer look at Dongguan Kingsun OptoelectronicLtd's potential here in our financial health report.
• Assess Dongguan Kingsun OptoelectronicLtd's previous results with our detailed historical performance reports.

Key Takeaways

• Embark on your investment journey to our 3,596 Global Penny Stocks selection here.
• Searching for a Fresh Perspective? Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com